# US 2025/0144105 A1 · Cdk9 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144105 A1
- Document ID: US20250144105A1
- Status: Published application
- Kind: A1
- Application number: 18/730,636
- Filed: 2023-01-19
- Published: 2025-05-08
- Earliest claimed: 2022-01-20
- Assignees: Origenis GmbH
- Applicants: Origenis GmbH
- Inventors: Roland Köstler; Jean Tassel; Michael Thormann
- Web page: https://patentgrep.com/patent/US20250144105A1

## CPC

- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- C07D 487/04: Ortho-condensed systems
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel compounds of formula (I): These compounds are inhibitors of CDK9 and are useful in the treatment of a variety of diseases including hyperproliferative diseases, virally induced infectious diseases, and cardiovascular diseases.

## Claims

### Claim 1

A compound of formula (I):
wherein
R1 is an alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, aralkyl or heteroaralkyl group; all of which groups may optionally be substituted;
R2 is a phenyl group that is substituted by 1, 2 or 3 substituents that are independently selected from the group consisting of F, Cl, Br and Me; and
R3 is a halogen atom, CN, a C1-4 alkyl group or a C1-4 heteroalkyl group;
or a salt or a solvate thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein R3 is Cl, Br, CN, CF3, a methyl group, an ethyl group or an isopropyl group.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein R3 is Cl.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein R2 is a phenyl group that is substituted in the 2 and 6 position.

### Claim 5 (depends on 1)

A compound according to claim 1, wherein R2 is a 2,6-difluorophenyl group, a 2,6-dichlorophenyl group or a 2-chloro-6-fluorophenyl group.

### Claim 6 (depends on 1)

A compound according to claim 1, wherein R2 is a 2,6-difluorophenyl group.

### Claim 7 (depends on 1)

A compound according to claim 1, wherein R1 is an optionally substituted C3-7 cycloalkyl group; an optionally substituted heterocycloalkyl group containing from 3 to 9 ring atoms that are independently selected from C, N and O; an optionally substituted phenyl group; an optionally substituted benzyl group; an optionally substituted heteroaryl group containing 5 or 6 ring atoms that are independently selected from C, N, O and S; or an optionally substituted heteroalkyl group containing from 1 to 12 carbon atoms and from 1 to 6 heteroatoms selected from N, O and S.

### Claim 8 (depends on 1)

A compound according to claim 1, wherein R1 is selected from the following groups:
wherein
R5 is a —NH2 group, a C1-6 heteroalkyl group or an optionally substituted heterocycloalkyl group containing 5 or 6 ring atoms that are independently selected from C, N and O.

### Claim 9 (depends on 1)

A compound according to claim 1, wherein R1 has the following structure:
wherein
R5 is a —NH2 group, a C1-6 heteroalkyl group or an optionally substituted heterocycloalkyl group containing 5 or 6 ring atoms that are independently selected from C, N and O.

### Claim 10 (depends on 8)

A compound according to claim 8, wherein R5 is selected from the following groups: —NH2, —NMe2, pyrrolidinyl, piperidinyl, N-methyl piperazinyl, morpholinyl, —NH(CH2)2F, —NH(CH2)3F, —NH(CH2)2OH, —NH(CH2)3OH, —NH(CH2)2OMe, —NH(CH2)3OMe, —N(Me)(CH2)2F, —N(Me)(CH2)3F, —N(Me)(CH2)2OH, —N(Me)(CH2)3OH, —N(Me)(CH2)2OMe, and —N(Me)(CH2)3OMe.

### Claim 11 (depends on 1)

A compound according to claim 1, wherein R1 is selected from the following groups:
wherein R5a is hydrogen, a C1-6 alkyl group, an optionally substituted C5-6 cycloalkyl group or an optionally substituted heterocycloalkyl group containing 5 or 6 ring atoms that are independently selected from C, N and O.

### Claim 12 (depends on 1)

A compound according to claim 1, wherein R1 is a group of formula —CH2—R1a or —CH2—CH2—R1a, wherein R1a is an optionally substituted heterocycloalkyl group having 5 or 6 ring atoms that are independently selected from C, N and O; or an optionally substituted heteroaryl group having 5 or 6 ring atoms that are independently selected from C, N, S and O.

### Claim 13 (depends on 8)

A compound according to claim 8, wherein the optional substituents are independently selected from C1-4 alkyl and C1-6 heteroalkyl.

### Claim 14 (depends on 1)

A compound according to claim 1 which is selected from the following compounds or a salt or a solvate thereof:
7-chloro-2-(2,6-difluorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)imidazo[2,1-f][1,2,4]triazin-4-amine;
(1r,4r)-N1-(7-chloro-2-(2,6-difluorophenyl)imidazo[2,1-f][1,2,4]triazin-4-yl)-N4,N4-dimethylcyclohexane-1,4-diamine;
(1r,4r)-N1-(7-chloro-2-(2,6-difluorophenyl)imidazo[2,1-f][1,2,4]triazin-4-yl)cyclohexane-1,4-diamine;
7-chloro-2-(2,6-difluorophenyl)-N-((1r,4r)-4-(piperidin-1-yl)cyclohexyl)imidazo[2,1-f][1,2,4]triazin-4-amine;
7-chloro-2-(2,6-difluorophenyl)-N-((1r,4r)-4-(pyrrolidin-1-yl)cyclohexyl)imidazo[2,1-f][1,2,4]triazin-4-amine;
(1r,4r)-N1-(7-chloro-2-(2,6-difluorophenyl)imidazo[2,1-f][1,2,4]triazin-4-yl)-N4-(2-methoxyethyl)cyclohexane-1,4-diamine;
(1r,4r)-N1-(7-chloro-2-(2,6-difluorophenyl)imidazo[2,1-f][1,2,4]triazin-4-yl)-N4-(2-fluoroethyl)cyclohexane-1,4-diamine;
(1r,4r)-N1-(7-chloro-2-(2,6-difluorophenyl)imidazo[2,1-f][1,2,4]triazin-4-yl)-N4-(3-fluoropropyl)cyclohexane-1,4-diamine;
7-chloro-2-(2,6-difluorophenyl)-N-(1-isopropylpiperidin-4-yl)imidazo[2,1-f][1,2,4]triazin-4-amine;
7-chloro-2-(2,6-difluorophenyl)-N-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)imidazo[2,1-f][1,2,4]triazin-4-amine;
7-chloro-N-(1-cyclopentylpiperidin-4-yl)-2-(2,6-difluorophenyl)imidazo[2,1-f][1,2,4]triazin-4-amine;
7-chloro-2-(2,6-difluorophenyl)-N-(1-methylpiperidin-4-yl)imidazo[2,1-f][1,2,4]triazin-4-amine;
[7-Chloro-2-(2,6-difluoro-phenyl)-imidazo[2,1-f][1,2,4]triazin-4-yl]-(1-methyl-piperidin-2-ylmethyl)-amine;
7-chloro-2-(2,6-difluorophenyl)-N-((1-ethylpyrrolidin-2-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine;
[7-Chloro-2-(2,6-difluoro-phenyl)-imidazo[2,1-f][1,2,4]triazin-4-yl]-piperidin-4-yl-amine;
[7-Chloro-2-(2,6-difluoro-phenyl)-imidazo[2,1-f][1,2,4]triazin-4-yl]-(1-methyl-piperidin-4-ylmethyl)-amine;
(1-Aza-bicyclo[2.2.2]oct-3-yl)-[7-chloro-2-(2,6-difluoro-phenyl)-imidazo[2,1-f][1,2,4]triazin-4-yl]-amine;
[7-Chloro-2-(2,6-difluoro-phenyl)-imidazo[2,1-f][1,2,4]triazin-4-yl]-(2-morpholin-4-yl-ethyl)-amine;
tert-butyl 3-(((7-chloro-2-(2,6-difluorophenyl)imidazo[2,1-f][1,2,4]triazin-4-yl)amino)methyl)piperidine-1-carboxylate;
7-chloro-2-(2,6-difluorophenyl)-N-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine;
7-chloro-2-(2,6-difluorophenyl)-N-(piperidin-3-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine;
N1-(7-chloro-2-(2,6-difluorophenyl)imidazo[2,1-f][1,2,4]triazin-4-yl)cyclopentane-1,3-diamine;
7-chloro-2-(2-chloro-6-fluorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)imidazo[2,1-f][1,2,4]triazin-4-amine;
7-chloro-2-(2,6-dichlorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)imidazo[2,1-f][1,2,4]triazin-4-amine;
2-(((1r,4r)-4-((7-chloro-2-(2,6-difluorophenyl)imidazo[2,1-f][1,2,4]triazin-4-yl)amino)cyclohexyl)amino)ethan-1-ol;
7-chloro-2-(2,6-difluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine;
7-chloro-2-(2,6-difluorophenyl)-N-((4,6-dimethylpyridin-3-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine; and
7-chloro-2-(2,6-difluorophenyl)-N-((1r,4r)-4-(4-methylpiperazin-1-yl)cyclohexyl)imidazo[2,1-f][1,2,4]triazin-4-amine.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and optionally one or more carrier substances and/or one or more adjuvants.

### Claim at position 16

-25. (canceled)

### Claim 26 (depends on 1)

A method for the treatment of one or more diseases in which abnormal CDK9 regulation is observed, including a broad number of cytokine-induced inflammatory, and autoimmune diseases, local or systemic viral infection diseases, viral infections of the eye, viral respiratory infections, or viral infections of the central and/or peripheral nervous system caused by DNA and/or RNA viruses, and various non-solid and solid malignancies, cancers, or hyperproliferative diseases such as acute myelogenous leukemia, chronic lymphocytic leukemia, relapsed multiple myeloma, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute biphenotypic leukemia, aggressive MYC-driven B-Cell lymphoma, primary peritoneal carcinoma, Kaposi sarcoma, advanced breast cancer, non-small cell lung cancer, colorectal cancer, or liver cancer such as hepatocellular carcinoma, cervical intraepithelial neoplasia, prostate cancer, melanoma, glioma, glioblastoma, neuroblastoma, astrocytoma, anaplastic astrocytoma or glioblastoma including advanced and/or metastatic haematological/solid malignancies (in particular, for use in the treatment of a hematologic malignancy, or a solid tumor caused by aberrant expression of MYC- or MCL-1); or for modulating the immune response and for the treatment and/or prevention of mechanical/injury-induced inflammation such as post-traumatic osteoarthritis (PTOA), systemic and local cytokine-induced inflammatory disease, including gastrointestinal or urinary tracts inflammatory diseases inflammatory diseases and inflammatory diseases of the eye, such as Sjogren's disease and glaucoma, bacteria-induced inflammatory disease, such as gingivitis, periodontitis, and for the treatment and/or prevention of cardiovascular diseases such as cardiac hypertrophy, dilated cardiomyopathy, atherosclerosis, and cardio-metabolic diseases such as obesity and diabetes;
which comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound according to claim 1, or of a salt or solvate thereof.

### Claim 27 (depends on 1)

A method for the treatment of local or systemic viral infection diseases, viral infections of the eye, viral respiratory infections, or viral infections of the central and/or peripheral nervous system caused by DNA and/or RNA viruses;
which comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound according to claim 1, or of a salt or solvate thereof.

### Claim 28 (depends on 1)

A method for the treatment of various non-solid and solid malignancies, cancers, or hyperproliferative diseases such as acute myelogenous leukemia, chronic lymphocytic leukemia, relapsed multiple myeloma, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute biphenotypic leukemia, aggressive MYC-driven B-Cell lymphoma, primary peritoneal carcinoma, Kaposi sarcoma, advanced breast cancer, non-small cell lung cancer, colorectal cancer, or liver cancer such as hepatocellular carcinoma, cervical intraepithelial neoplasia, prostate cancer, melanoma, glioma, glioblastoma, neuroblastoma, astrocytoma, anaplastic astrocytoma or glioblastoma including advanced and/or metastatic haematological/solid malignancies (in particular, for use in the treatment of a hematologic malignancy, or a solid tumor caused by aberrant expression of MYC- or MCL-1);
which comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound according to claim 1, or of a salt or solvate thereof.

### Claim 29 (depends on 1)

A method for the treatment of inflammation related diseases—including a broad number of cytokine-induced inflammatory, and autoimmune diseases, or for modulating the immune response and for the treatment and/or prevention of mechanical/injury-induced inflammation such as post-traumatic osteoarthritis (PTOA), systemic and local cytokine-induced inflammatory disease, including gastrointestinal or urinary tracts inflammatory diseases inflammatory diseases and inflammatory diseases of the eye, such as Sjogren's disease and glaucoma, bacteria-induced inflammatory disease, such as gingivitis, periodontitis, and for the treatment and/or prevention of cardiovascular diseases such as, dilated cardiomyopathy, atherosclerosis, cardiac hypertrophy and cardio-metabolic diseases such as obesity and diabetes;
which comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound according to claim 1, or of a salt or solvate thereof.

### Claim 30 (depends on 26)

A method for the treatment of a combination of two or more of the diseases according to claim 26;
which comprises administering to a subject in need of such treatment the therapeutically effective amount of the compound, or of the salt or solvate thereof.
